Cosmetic News In Brief: J&J Incurs Third Talc Trial Loss; Lauder Acquires BECCA; More

J&J again failed to convince a St. Louis jury that available evidence does not support alleged links between its Johnson’s Baby Powder and cases of ovarian cancer, marking the third costly loss in the Missouri circuit court this year; More cosmetics news in brief.

Firm says it will appeal an Oct. 27 jury finding in Missouri’s 22nd Circuit Court, which awarded nearly $71m to a woman claiming to have developed ovarian cancer as a result of decades-long use of Johnson & Johnson talcum powder products for feminine hygiene purposes. According to a same-day blog post from Courtroom View Network, which webcast the trial “gavel-to-gavel,” J&J has been ordered to pay plaintiff Deborah Giannecchini $67.5m in punitive damages and $2.57m in compensatory damages in the third costly verdict against the firm in the St. Louis court this year. This time, J&J’s talc supplier Imerys Talc America also was found partially responsible, which puts it on the hook for covering 10% of the compensatory damages and $2.5m of the total punitive award, the CVN post notes. J&J maintains the safety of Johnson’s Baby Powder, telling CVN that it is “guided by the science” in its plan to appeal.

Thousands more suits have been filed against the firm, primarily in Missouri and New Jersey courts. The latter have proven...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Deals

Nancy Tests Arc AI Editor

 
• By 

Curve Biosciences has developed a "Whole-Body Intelligence" platform using cfDNA from blood to monitor chronic diseases, starting with the liver. Focused on liver cirrhosis and MASH, the company aims to aid in treatment decisions and plans to expand into monitoring other organs.

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

L’Oreal Acquires 10% Stake, Plans R&D Collaboration With Galderma

 

L’Oréal and Galderma have signed a memorandum of understanding to collaborate on complementary research projects to discover ‘new avenues and accelerate innovation’ in the field of dermatology. L’Oreal has arranged to purchase a 10% stake in its partner.

More from Business

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.